Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Tax Provisions (2023 - 2025)

Krystal Biotech (KRYS) has disclosed Tax Provisions for 3 consecutive years, with -$260000.0 as the latest value for Q4 2025.

  • Quarterly Tax Provisions fell 108.4% to -$260000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$15.4 million through Dec 2025, down 348.69% year-over-year, with the annual reading at -$15.4 million for FY2025, 347.86% down from the prior year.
  • Tax Provisions hit -$260000.0 in Q4 2025 for Krystal Biotech, up from -$31.4 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $8.4 million in Q2 2025 to a low of -$31.4 million in Q3 2025.
  • Historically, Tax Provisions has averaged -$901875.0 across 3 years, with a median of $2.3 million in 2023.
  • Biggest YoY gain for Tax Provisions was 1669.81% in 2025; the steepest drop was 1307.69% in 2025.
  • Year by year, Tax Provisions stood at $2.0 million in 2023, then skyrocketed by 57.61% to $3.1 million in 2024, then crashed by 108.4% to -$260000.0 in 2025.
  • Business Quant data shows Tax Provisions for KRYS at -$260000.0 in Q4 2025, -$31.4 million in Q3 2025, and $8.4 million in Q2 2025.